TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

This is a Phase 1/1b, multicenter, open-label, non-randomized, multi-cohort study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TT-10 (A2A receptor antagonist) and TT-4 Diacid (A2B receptor antagonist) administered orally as single agents and, in selected participants, as a sequential add-on combination regimen in participants with advanced selected solid tumors. This study is planned to be conducted at approximately 5 sites in Unites States. The study consists of a Phase 1 dose escalation/safety lead-in and a Phase 1b dose/regimen optimization (and limited expansion, if applicable). All participants will undergo pre-treatment screening, on-study assessments for safety and clinical activity, and post-treatment follow-up for at least 30 days (+7 days) after the final dose. A treatment cycle is defined as 28 days.